Max Healthcare Institute has informed that the Board of Directors at their meeting held today, August 10, 2022 have considered and approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2022 (UFRs); Convening of 21st Annual General Meeting (AGM) of the Company on Monday, September 26, 2022 through Video Conferencing/ Other Audio Visual Means. Notice of AGM and other requisite documents will be circulated to shareholders in due course, besides intimation to stock exchanges; Enabling approval to infuse funds in two wholly-owned subsidiaries of the Company up to Rs 100 Crore in Hometrail Buildtech for financing its business expansion plan and up to Rs 15 Crore in Max Lab for meeting its existing and future fund requirements, by way of investment in equity/ preference shares and/or granting of loan etc in one or more tranches; On the recommendation of Nomination & Remuneration Committee (NRC) and Audit & Risk Management Committee, re-appointment of Abhay Soi (DIN-00203597) as the Chairman and Managing Director (CMD) for a further period of three years with effective from June 19, 2023 to June 18, 2026 and approval of terms & conditions thereof, subject to necessary compliances and approvals under the Companies Act, 2013 and Listing Regulations. On the recommendation of NRC, appointment of Pranav Chirayu Amin (DIN-00245099) as an additional director with effective from August 10, 2022, to hold office up to the date of ensuing AGM of the Company and as an independent director for a term of 5 consecutive years with effective from August 10, 2022, subject to the approval of members of the Company. The details as required under Listing Regulations read with September 9 Circular is given in ‘Annexure C’ to this letter.
The above information is a part of company’s filings submitted to BSE.